---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-036020"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2022-06-30T23:59:59+00:00"
generated_at: "2026-06-24T22:09:56.646673+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics CEO Steve Carchedi and CFO Jens Knudsen resign; James Cullem interim CEO, Joan Brown interim CFO

## Summary
- CEO Steve Carchedi resigned effective June 29, 2022; CFO Jens Knudsen resigned effective June 27, 2022, both to pursue other opportunities.
- Board appointed James Cullem, current Chief Business Officer, as interim CEO; he continues as CBO.
- Board appointed Joan Brown, current Director of Financial Reporting, as interim CFO; she continues as Director of Financial Reporting.
- Permanent CEO and CFO expected to be named in H1 2023, per press release.
- Co-founders Dr. Steen Knudsen (CSO) and Dr. Marie Foegh (CMO) remain in roles; Thomas Jensen becomes SVP of Investor Relations.

## SEC filing metadata
- accession: 0001213900-22-036020
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2022-06-30T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/0001213900-22-036020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/ea162285-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-036020
- JSON: https://secwatch.observer/filing/0001213900-22-036020.json
- Plain text: https://secwatch.observer/filing/0001213900-22-036020.txt

## Key facts
- Executive change
  James Cullem was appointed as interim Chief Executive Officer at Allarity Therapeutics, Inc..
  - Action: appointed
  - Role: interim Chief Executive Officer
  source text: the Board of Directors of the Company (the “Board”) appointed James Cullem, the Company’s current Chief Business Officer, as the interim Chief Executive Officer of the Company effective as of June 29, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/0001213900-22-036020-index.htm
- Executive change
  Steve Carchedi resigned as Chief Executive Officer at Allarity Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: Effective as of June 29, 2022, Steve Carchedi resigned from all positions in Allarity Therapeutics, Inc. (the “Company”), and all positions of its subsidiaries, including his role of Chief Executive Officer and as a director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/0001213900-22-036020-index.htm
- Executive change
  Jens Knudsen resigned as Chief Financial Officer at Allarity Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Effective as of June 27, 2022, Jens Knudsen resigned from all positions in the Company, and all positions of its subsidiaries, including his role of Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/0001213900-22-036020-index.htm
- Executive change
  Joan Brown was appointed as interim Chief Financial Officer at Allarity Therapeutics, Inc..
  - Action: appointed
  - Role: interim Chief Financial Officer
  source text: the Board appointed Joan Brown, the Company’s current Director of Financial Reporting, as the interim Chief Financial Officer of the Company effective as of June 29, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/0001213900-22-036020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.